These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25410489)

  • 1. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
    Kim HJ; Im SA; Keam B; Ham HS; Lee KH; Kim TY; Kim YJ; Oh DY; Kim JH; Han W; Jang IJ; Kim TY; Park IA; Noh DY
    Cancer Sci; 2015 Jan; 106(1):86-93. PubMed ID: 25410489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
    Kim KP; Ahn JH; Kim SB; Jung KH; Yoon DH; Lee JS; Ahn SH
    Cancer Chemother Pharmacol; 2012 May; 69(5):1221-7. PubMed ID: 22271208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy.
    Ikeda M; Tsuji D; Yamamoto K; Kim YI; Daimon T; Iwabe Y; Hatori M; Makuta R; Hayashi H; Inoue K; Nakamichi H; Shiokawa M; Itoh K
    Drug Metab Pharmacokinet; 2015 Apr; 30(2):149-53. PubMed ID: 25989890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients.
    Lévy P; Gligorov J; Antoine M; Rezai K; Lévy E; Selle F; Saintigny P; Lokiec F; Avenin D; Beerblock K; Lotz JP; Bernaudin JF; Fajac A
    Breast Cancer Res Treat; 2013 Jun; 139(2):421-8. PubMed ID: 23666532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Nov; 7():203. PubMed ID: 17976237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients.
    Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Segura-Pérez AM; Chamorro-Santos C; Vergara-Alcaide E; Castillo-Portellano L; Calleja-Hernández MÁ
    Pharmacol Res; 2016 Jun; 108():111-118. PubMed ID: 27137881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD24 polymorphisms cannot predict pathologic complete response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer.
    Zhou X
    Clin Breast Cancer; 2014 Apr; 14(2):e33-40. PubMed ID: 24393851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.
    Ludovini V; Antognelli C; Rulli A; Foglietta J; Pistola L; Eliana R; Floriani I; Nocentini G; Tofanetti FR; Piattoni S; Minenza E; Talesa VN; Sidoni A; Tonato M; Crinò L; Gori S
    BMC Cancer; 2017 Jul; 17(1):502. PubMed ID: 28747156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
    Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
    Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.
    Wu H; Kang H; Liu Y; Tong W; Liu D; Yang X; Lian M; Yao W; Zhao H; Huang D; Sha X; Wang E; Wei M
    J Cancer Res Clin Oncol; 2012 Sep; 138(9):1449-62. PubMed ID: 22526155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
    Loibl S; Müller BM; von Minckwitz G; Schwabe M; Roller M; Darb-Esfahani S; Ataseven B; du Bois A; Fissler-Eckhoff A; Gerber B; Kulmer U; Alles JU; Mehta K; Denkert C
    Breast Cancer Res Treat; 2011 Nov; 130(2):477-87. PubMed ID: 21837479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India.
    Priyadarshini R; Raj GM; Kayal S; Ramesh A; Shewade DG
    J Clin Pharm Ther; 2019 Apr; 44(2):188-196. PubMed ID: 30637776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
    Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
    Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
    Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
    Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
    Zhai L; Li S; Li X; Li H; Gu F; Guo X; Liu F; Zhang X; Fu L
    Pathol Res Pract; 2015 Feb; 211(2):130-7. PubMed ID: 25480692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
    Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
    Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients.
    Turiján-Espinoza E; Ruíz-Rodríguez VM; Uresti-Rivera EE; Martínez-Leija E; Zermeño-Nava JJ; Guel-Pañola A; Romano-Moreno S; Vargas-Morales JM; Portales-Pérez DP
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):843-853. PubMed ID: 33740100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.
    Shitara K; Matsuo K; Ito S; Sawaki A; Kawai H; Yokota T; Takahari D; Shibata T; Ura T; Ito H; Hosono S; Kawase T; Watanabe M; Tajima K; Yatabe Y; Tanaka H; Muro K
    Asian Pac J Cancer Prev; 2010; 11(2):447-52. PubMed ID: 20843132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
    Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
    Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated gene expression profile predicts prognosis of breast cancer patients.
    Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
    Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.